In a 57-year-old male who underwent a second 1800 mg BioTE testosterone pellet insertion and is taking dimethyl sulfone (DIM) 2 tablets daily, with recent labs showing hemoglobin 16.2 g/dL, hematocrit 48.6 % and SHBG 36 nmol/L, what management steps should be taken?

Management of Elevated Hematocrit in a 57-Year-Old Male on Testosterone Pellet Therapy

Immediate Assessment and Action

Continue current testosterone pellet therapy without intervention, as the hematocrit of 48.6% remains well below the 54% safety threshold that mandates immediate cessation. 1, 2, 3

The patient's laboratory values show:

• Hemoglobin 16.2 g/dL (normal range)
• Hematocrit 48.6% (below the critical 54% threshold)
• SHBG 36 nmol/L (within normal range)

These values indicate appropriate erythropoietic response to testosterone therapy without reaching levels that require dose modification or treatment interruption.

Why No Intervention Is Required at This Time

• The Endocrine Society explicitly states that testosterone therapy must be stopped only when hematocrit exceeds 54%, not at lower values. 1, 2, 3
• A baseline hematocrit >50% is considered a relative contraindication to initiating therapy, but this patient's current value of 48.6% does not meet that threshold and he is already established on treatment. 1, 2
• Testosterone pellets produce a mean hematocrit increase of only 2.2% in clinical studies, which is statistically significant but clinically modest and unlikely to cause harm. 4
• The patient's hematocrit of 48.6% provides a safety margin of 5.4 percentage points below the mandatory discontinuation threshold of 54%. 1, 2, 3

Monitoring Schedule Going Forward

Hematocrit Surveillance

• Recheck hematocrit in 3 months (at the next routine monitoring interval) to assess trajectory, as testosterone-induced erythrocytosis is dose-dependent and may progress over time. 1, 2, 3
• If hematocrit rises above 54% at any future visit, immediately discontinue testosterone therapy, evaluate for hypoxia and obstructive sleep apnea, and consider restarting only after normalization at a reduced dose. 1, 2, 3
• Continue annual hematocrit monitoring once levels stabilize, as polycythemia can develop insidiously even when testosterone levels remain constant. 1, 2

Testosterone Level Assessment

• Measure total, free, and bioavailable testosterone at 6 weeks post-insertion (as already planned) to confirm mid-normal range of 400–700 ng/dL. 1, 2, 3
• For testosterone pellets, obtain the level at the end of the dosing interval to guide adjustment of pellet number or insertion frequency. 2
• Adjust therapy if testosterone exceeds 700 ng/dL or falls below 400 ng/dL by modifying the number of pellets or the interval between insertions. 1, 2

Estradiol Monitoring

• Check free estradiol at 6 weeks (as planned) because this patient has a history of elevated estradiol and pellet extrusion, both of which suggest increased aromatization. 1, 2
• Continue DIM 2 tablets daily as prescribed to inhibit aromatase activity and prevent recurrent estrogen excess. (No specific citation for DIM efficacy in guidelines, but continuation is appropriate given prior response.)

Prostate Surveillance

• Obtain PSA and digital rectal examination at the 6-week visit (if not done recently), then repeat at 6 months and annually thereafter. 1, 2, 3
• Refer to urology immediately if any of the following occur:
  • PSA increase >1.4 ng/mL within any 12-month period
  • PSA velocity >0.4 ng/mL per year (requires ≥2 years of data)
  • Abnormal digital rectal examination
  • AUA/IPSS symptom score >19 1, 2, 3

Risk Stratification for Future Hematocrit Elevation

• Pretreatment hematocrit is inversely related to the magnitude of hematocrit increase during testosterone therapy, meaning patients starting with lower baseline values (like this patient's implied pre-treatment level) tend to experience larger rises. 4
• Injectable testosterone formulations carry a 43.8% incidence of hematocrit >52%, compared to 11.3–17.9% for gels and 2.8–15.4% for patches; pellet data are limited but appear intermediate. 5
• Recent evidence demonstrates that any increase in hematocrit from baseline after starting testosterone therapy is associated with increased risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and death. 6
• The cardiovascular risk associated with hematocrit elevation appears to be continuous rather than threshold-based, meaning even modest rises below 54% may confer some degree of increased thrombotic risk. 6

When to Consider Dose Reduction or Formulation Change

• If hematocrit rises to 52–53% at the next visit (still below the 54% mandatory stop threshold), consider reducing the pellet dose from 1800 mg to 1600 mg or switching to a weekly intramuscular regimen (100 mg testosterone cypionate weekly), which produces more stable levels and lower peak hematocrit values. 7
• Weekly 100 mg intramuscular testosterone cypionate is associated with only a 1% incidence of hematocrit >54%, compared to 8% with 200 mg every 2 weeks, making it a safer alternative if erythrocytosis becomes problematic. 7
• Transdermal testosterone formulations (gels or patches) produce the lowest rates of erythrocytosis and may be preferable if hematocrit continues to rise despite dose reduction. 5

Common Pitfalls to Avoid

• Do not discontinue testosterone therapy at a hematocrit of 48.6%, as this is premature and not supported by any guideline; the 54% threshold is absolute and evidence-based. 1, 2, 3
• Do not perform therapeutic phlebotomy at this hematocrit level, as evidence supporting its efficacy or safety in testosterone-induced erythrocytosis is lacking, and phlebotomy may paradoxically increase thrombotic risk by lowering tissue oxygen and depleting iron stores. 8
• Do not wait until hematocrit exceeds 54% to begin planning alternative strategies; proactive dose adjustment or formulation change at 52–53% can prevent the need for treatment interruption. 9
• Do not ignore the patient's history of pellet extrusion and elevated estradiol, as these suggest suboptimal pellet placement or excessive aromatization that may require technique modification or increased aromatase inhibition. 1, 2

Summary Algorithm

1. Current hematocrit 48.6% → Continue 1800 mg pellets and DIM 2 tablets daily
2. Recheck hematocrit in 3 months:
   • If <52% → Continue current regimen with annual monitoring
   • If 52–53% → Consider dose reduction to 1600 mg pellets or switch to 100 mg weekly IM cypionate
   • If ≥54% → Stop testosterone immediately, evaluate for hypoxia/sleep apnea, restart at reduced dose only after normalization 1, 2, 3
3. Monitor testosterone and estradiol at 6 weeks to confirm mid-normal range and adequate aromatase inhibition 1, 2
4. Continue PSA and DRE surveillance at 6 months and annually 1, 2, 3